MedTrace Logo

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-07-21

Study results available
· View outcomes & findings →

Summary

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812

Conditions

  • Alzheimer Disease

Interventions

DRUG

300 mg [C14] CT1812

Single dose of 300 mg CT1812 with microtracer dose of \[C14\]

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Anthony Caggiano, MD · Cognition Therapeutics Inc.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-01-17
Completion
2022-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225389 on ClinicalTrials.gov